QR kód

Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study

IntroductionClazosentan, a selective endothelin receptor subtype A antagonist, reduces vasospasm-related morbidity and all-cause mortality following aneurysmal subarachnoid hemorrhage (SAH) in the Japanese population, as demonstrated by a recent randomized phase 3 trial. However, evidence to suggest...

Celý popis

Uloženo v:
Hlavní autoři: Hiroyuki Sakata, Atsushi Kanoke, Hiroki Uchida, Shinya Haryu, Shunsuke Omodaka, Naoto Kimura, Masahiro Yoshida, Kuniyasu Niizuma, Teiji Tominaga, Hidenori Endo
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2024-06-01
Edice:Frontiers in Neurology
Témata:
subarachnoid hemorrhage
cerebral vasospasm
delayed cerebral ischemia
delayed ischemic neurologic deficit
clazosentan
endothelin
On-line přístup:https://www.frontiersin.org/articles/10.3389/fneur.2024.1413632/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky